Pharnext SA announced that it expects to receive 21.0938 million in funding from Neovacs S.A.
On the same date, the company issued 107,000 bonds for gross proceeds of 10,700,000 million in its first tranche. The remaining funding is done in ten additional tranches, including two tranches of a net amount of 2.5 million, respectively, in October and November 2022, then of 1 million net, respectively, in December 2022 and January 2023, and finally of 500,000 net per month from February 2023 to July 2023 inclusive.